Cargando…
Expanding the role of PSMA PET in active surveillance
INTRODUCTION: Accurate grading at the time of diagnosis is fundamental to risk stratification and treatment decision making, particularly for men being considered for Active Surveillance (AS). With the introduction of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) there...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149016/ https://www.ncbi.nlm.nih.gov/pubmed/37120544 http://dx.doi.org/10.1186/s12894-023-01219-4 |
_version_ | 1785035084389154816 |
---|---|
author | Jain, Anika Nassour, Anthony-Joe Dean, Thomas Patterson, Imogen Tarlinton, Lisa Kim, Lawrence Woo, Henry |
author_facet | Jain, Anika Nassour, Anthony-Joe Dean, Thomas Patterson, Imogen Tarlinton, Lisa Kim, Lawrence Woo, Henry |
author_sort | Jain, Anika |
collection | PubMed |
description | INTRODUCTION: Accurate grading at the time of diagnosis is fundamental to risk stratification and treatment decision making, particularly for men being considered for Active Surveillance (AS). With the introduction of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) there has been considerable improvement in sensitivity and specificity for the detection and staging of clinically significant prostate cancer. Our study aims to determine the role of PSMA PET/CT in men with newly diagnosed low or favourable intermediate risk prostate cancer to better select men for AS. METHOD: This is a retrospective single centre study performed from January 2019 and October 2022. This study includes men identified from electronic medical record system who had undergone a PSMA PET/CT following newly diagnosed low or favourable-intermediate risk prostate cancer. Primary outcome was to assess the change in management for men being considered for AS following PSMA PET/CT results on the basis of PSMA PET characteristics. RESULTS: In total, there were 11 of 30 men (36.67%) who were assigned management by AS and 19 of 30 men (63.33%) who had definitive treatment. 15 of the 19 men that needed treatment had concerning features on PSMA PET/CT results. Of the 15 men with concerning features on PSMA PET, 9 (60%) men were found to have adverse pathological features on final prostatectomy features. CONCLUSION: This retrospective study suggests that PSMA PET/CT has potential to influence the management of men with newly diagnosed prostate cancer that would otherwise be appropriate for active surveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01219-4. |
format | Online Article Text |
id | pubmed-10149016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101490162023-05-01 Expanding the role of PSMA PET in active surveillance Jain, Anika Nassour, Anthony-Joe Dean, Thomas Patterson, Imogen Tarlinton, Lisa Kim, Lawrence Woo, Henry BMC Urol Research INTRODUCTION: Accurate grading at the time of diagnosis is fundamental to risk stratification and treatment decision making, particularly for men being considered for Active Surveillance (AS). With the introduction of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) there has been considerable improvement in sensitivity and specificity for the detection and staging of clinically significant prostate cancer. Our study aims to determine the role of PSMA PET/CT in men with newly diagnosed low or favourable intermediate risk prostate cancer to better select men for AS. METHOD: This is a retrospective single centre study performed from January 2019 and October 2022. This study includes men identified from electronic medical record system who had undergone a PSMA PET/CT following newly diagnosed low or favourable-intermediate risk prostate cancer. Primary outcome was to assess the change in management for men being considered for AS following PSMA PET/CT results on the basis of PSMA PET characteristics. RESULTS: In total, there were 11 of 30 men (36.67%) who were assigned management by AS and 19 of 30 men (63.33%) who had definitive treatment. 15 of the 19 men that needed treatment had concerning features on PSMA PET/CT results. Of the 15 men with concerning features on PSMA PET, 9 (60%) men were found to have adverse pathological features on final prostatectomy features. CONCLUSION: This retrospective study suggests that PSMA PET/CT has potential to influence the management of men with newly diagnosed prostate cancer that would otherwise be appropriate for active surveillance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01219-4. BioMed Central 2023-04-29 /pmc/articles/PMC10149016/ /pubmed/37120544 http://dx.doi.org/10.1186/s12894-023-01219-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jain, Anika Nassour, Anthony-Joe Dean, Thomas Patterson, Imogen Tarlinton, Lisa Kim, Lawrence Woo, Henry Expanding the role of PSMA PET in active surveillance |
title | Expanding the role of PSMA PET in active surveillance |
title_full | Expanding the role of PSMA PET in active surveillance |
title_fullStr | Expanding the role of PSMA PET in active surveillance |
title_full_unstemmed | Expanding the role of PSMA PET in active surveillance |
title_short | Expanding the role of PSMA PET in active surveillance |
title_sort | expanding the role of psma pet in active surveillance |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149016/ https://www.ncbi.nlm.nih.gov/pubmed/37120544 http://dx.doi.org/10.1186/s12894-023-01219-4 |
work_keys_str_mv | AT jainanika expandingtheroleofpsmapetinactivesurveillance AT nassouranthonyjoe expandingtheroleofpsmapetinactivesurveillance AT deanthomas expandingtheroleofpsmapetinactivesurveillance AT pattersonimogen expandingtheroleofpsmapetinactivesurveillance AT tarlintonlisa expandingtheroleofpsmapetinactivesurveillance AT kimlawrence expandingtheroleofpsmapetinactivesurveillance AT woohenry expandingtheroleofpsmapetinactivesurveillance |